Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma

An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up

F. A. Mauri, O. Caffo, S. Veronese, P. Verderio, P. Boracchi, M. Bonzanini, N. Rossi, G. Perrone, P. Dalla Palma, M. Barbareschi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a series of 252 consecutive cases of infiltrating breast carcinomas (104 N0, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor (ER) status has been evaluated with the immunohistochemical method (ER1 D5 antibody, 10% cut-off value): 121 cases were ER negative, 128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal status and tumour size.

Original languageEnglish
Pages (from-to)1661-1668
Number of pages8
JournalBritish Journal of Cancer
Volume77
Issue number10
Publication statusPublished - 1998

Fingerprint

Antigen Receptors
Carcinoembryonic Antigen
Estrogen Receptors
Outcome Assessment (Health Care)
Breast Neoplasms
Staining and Labeling
Survival Analysis
Tumor Biomarkers
Clinical Studies
Multivariate Analysis
Monoclonal Antibodies
Drug Therapy
Antibodies
Therapeutics
Neoplasms

Keywords

  • Breast neoplasm
  • Carcinoembryonic antigen
  • Immunohistochemistry
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma : An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. / Mauri, F. A.; Caffo, O.; Veronese, S.; Verderio, P.; Boracchi, P.; Bonzanini, M.; Rossi, N.; Perrone, G.; Dalla Palma, P.; Barbareschi, M.

In: British Journal of Cancer, Vol. 77, No. 10, 1998, p. 1661-1668.

Research output: Contribution to journalArticle

Mauri, FA, Caffo, O, Veronese, S, Verderio, P, Boracchi, P, Bonzanini, M, Rossi, N, Perrone, G, Dalla Palma, P & Barbareschi, M 1998, 'Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up', British Journal of Cancer, vol. 77, no. 10, pp. 1661-1668.
Mauri, F. A. ; Caffo, O. ; Veronese, S. ; Verderio, P. ; Boracchi, P. ; Bonzanini, M. ; Rossi, N. ; Perrone, G. ; Dalla Palma, P. ; Barbareschi, M. / Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma : An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. In: British Journal of Cancer. 1998 ; Vol. 77, No. 10. pp. 1661-1668.
@article{ec06dbba42dc4801a862042ebba4d750,
title = "Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up",
abstract = "Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a series of 252 consecutive cases of infiltrating breast carcinomas (104 N0, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor (ER) status has been evaluated with the immunohistochemical method (ER1 D5 antibody, 10{\%} cut-off value): 121 cases were ER negative, 128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal status and tumour size.",
keywords = "Breast neoplasm, Carcinoembryonic antigen, Immunohistochemistry, Prognosis",
author = "Mauri, {F. A.} and O. Caffo and S. Veronese and P. Verderio and P. Boracchi and M. Bonzanini and N. Rossi and G. Perrone and {Dalla Palma}, P. and M. Barbareschi",
year = "1998",
language = "English",
volume = "77",
pages = "1661--1668",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma

T2 - An immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up

AU - Mauri, F. A.

AU - Caffo, O.

AU - Veronese, S.

AU - Verderio, P.

AU - Boracchi, P.

AU - Bonzanini, M.

AU - Rossi, N.

AU - Perrone, G.

AU - Dalla Palma, P.

AU - Barbareschi, M.

PY - 1998

Y1 - 1998

N2 - Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a series of 252 consecutive cases of infiltrating breast carcinomas (104 N0, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor (ER) status has been evaluated with the immunohistochemical method (ER1 D5 antibody, 10% cut-off value): 121 cases were ER negative, 128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal status and tumour size.

AB - Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a series of 252 consecutive cases of infiltrating breast carcinomas (104 N0, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor (ER) status has been evaluated with the immunohistochemical method (ER1 D5 antibody, 10% cut-off value): 121 cases were ER negative, 128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal status and tumour size.

KW - Breast neoplasm

KW - Carcinoembryonic antigen

KW - Immunohistochemistry

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=7144226570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144226570&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 1661

EP - 1668

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -